Meridian Life Science, Inc.: Meridian Bioscience Reports Strong Fourth Quarter and Record Full-Year Fiscal 2020 Operating Results and Provides Fiscal 2021 Guidance

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2020. Fourth Quarter 2020 Highlights (Comparison to Fourth Quarter Fiscal 2019): Consolidated Net Revenue of $64.2 million, up 26% year-over-year Life Science segment delivers revenue of $34.4 million, up 97% year-over-year Diagnostics segment revenues decreased 11% year-over-year to $29.8 million, a stronger